Anosmia, the clinical term for the inability to smell. This disorder impair the ability to sense odors in the environment, as well as hinder the quality of life related to social interactions, eating, and feelings of well-being. It is a severe disability, affected genetically or accidentally, resulting in total/partial absence of olfactory guidance.

Market Dynamics

Rising anosmia cases is the major factor that is expected to drive growth of the global anosmia market during the forecast period. For instance, according to an article published by the National Institute on Deafness and Other Communication Disorders in February 2019, around 3% of U.S. populace have anosmia i.e.no sense of smell.

Market players are focusing on research and development activities for offering novel products for the treatment anosmia, which is expected to drive the market growth over the forecast period. For instance, in July 2020, Zydus Cadila received the U.S. Food & Drug Administration (U.S. FDA) approval for its supplemental abbreviated new drug application (SANDA) for Doxycycline Injection USP, 100 mg/vial, which seems to improve respiratory symptoms and anosmia  

Key features of the study

• This report provides in-depth analysis of the global anosmia market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global anosmia market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Mylan N.V., Pfizer Inc., Atom Pharma, RANBAXY LABORATORIES LIMITED, Alde Medi Impex, GlaxoSmithkline plc, Sandoz (Novasrtis AG), Inke S.A., Taj Pharmaceuticals Limited, and Sanofi, amongst others.
• Insights from this report would allow marketers and management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
• The global anosmia market report caters to various stakeholders in this industry including investors, suppliers, anosmia manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global anosmia market.

Anosmia Market Segmentation (Revenue, USD Bn, 2021-2033)

• By Type
  • Idiopathic Anosmia
  • Congenital Anosmia
• By Treatment  (Revenue, USD Bn, 2021-2033)
  • Therapies
  • Nasal Endoscopy
  • Imaging
  • Medications
  • Decongestants
  • Antihistamines
  • Steroid Nasal Sprays
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Mylan N.V.
  • Pfizer Inc.
  • Atom Pharma
  • RANBAXY LABORATORIES LIMITED
  • Alde Medi Impex
  • GlaxoSmithkline plc
  • Sandoz (Novasrtis AG)
  • Inke S.A.
  • Taj Pharmaceuticals Limited
  • Sanofi